Here are seven points:
1. The treatment, SER-109, is intended for multiply recurrent Clostridium difficile infection.
2. The study enrolled 89 subjects with multiply recurrent CDI, which is defined as three or more recent recurrences.
3. The randomized, double-blind, placebo-controlled 24-week study aimed to evaluate the safety and efficacy of SER-109.
4. Based on the eight-week data, the researchers did not see any difference in the adverse event frequency or type in the patients receiving SER-109 as compared to those receiving placebo.
5. The most commonly reported adverse events in both the SER-109 and placebo groups were in the gastrointestinal category.
6. Roger Pomerantz, MD, president, chairman and CEO of Seres said these were unexpected “in view of the positive data in our prior investigator-sponsored Phase 1b trial, as well as in a wide range of supporting clinical and preclinical data.”
7. Seres Therapeutics stock plummeted 78 percent in pre-market trade on July 29, following the news of the trial results.
More articles on GI/endoscopy:
5 most read GI/endoscopy stories: July 25 — July 29
Dr. Mubashar Munir to lead Walk with a Doc event at Piedmont Newnan Hospital: 3 points
FDA approves AbbVie’s VIEKIRA XR for HCV treatment: 5 notes
